Analysis of different HER-2 mutations in breast cancer progression and drug resistance
出版年份 2015 全文链接
标题
Analysis of different HER-2 mutations in breast cancer progression and drug resistance
作者
关键词
-
出版物
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
Volume 19, Issue 12, Pages 2691-2701
出版商
Wiley
发表日期
2015-08-25
DOI
10.1111/jcmm.12662
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- HER2 gene mutations in non-small cell lung carcinomas: Concurrence with her2 gene amplification and her2 protein expression and phosphorylation
- (2015) Mikiko Suzuki et al. LUNG CANCER
- Morphological and molecular characteristics of HER2 amplified urothelial bladder cancer
- (2015) J. Tschui et al. VIRCHOWS ARCHIV
- Updated Meta-analysis on HER2 Polymorphisms and Risk of Breast Cancer: Evidence from 32 Studies
- (2015) Wei Chen et al. Asian Pacific Journal of Cancer Prevention
- HER2 aberrations in cancer: Implications for therapy
- (2014) Min Yan et al. CANCER TREATMENT REVIEWS
- Quantitative Measurements of Tumoral p95HER2 Protein Expression in Metastatic Breast Cancer Patients Treated with Trastuzumab: Independent Validation of the p95HER2 Clinical Cutoff
- (2014) R. Duchnowska et al. CLINICAL CANCER RESEARCH
- Resistance to human epidermal growth factor receptor type 2-targeted therapies
- (2014) Jean-Christophe Thery et al. EUROPEAN JOURNAL OF CANCER
- P95 HER2 fragments and breast cancer outcome
- (2014) Deniz Tural et al. Expert Review of Anticancer Therapy
- HER2 Mutation Status in Japanese HER2-negative Breast Cancer Patients
- (2014) Y. Endo et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- Biomarker Analyses in CLEOPATRA: A Phase III, Placebo-Controlled Study of Pertuzumab in Human Epidermal Growth Factor Receptor 2–Positive, First-Line Metastatic Breast Cancer
- (2014) José Baselga et al. JOURNAL OF CLINICAL ONCOLOGY
- Trastuzumab Plus Adjuvant Chemotherapy for Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Planned Joint Analysis of Overall Survival From NSABP B-31 and NCCTG N9831
- (2014) Edith A. Perez et al. JOURNAL OF CLINICAL ONCOLOGY
- Effect of p95HER2/611CTF on the Response to Trastuzumab and Chemotherapy
- (2014) Josep Lluís Parra-Palau et al. JNCI-Journal of the National Cancer Institute
- HER family kinase domain mutations promote tumor progression and can predict response to treatment in human breast cancer
- (2014) Delphine R. Boulbes et al. Molecular Oncology
- Treatment of Metastatic Extramammary Paget's Disease Associated With Adnexal Adenocarcinoma, With Anti-HER2 Drugs Based on Genomic Alteration ERBB2 S310F
- (2014) O. Vornicova et al. ONCOLOGIST
- Modulation of ErbB2 Blockade in ErbB2-Positive Cancers: The Role of ErbB2 Mutations and PHLDA1
- (2014) Guangyuan Li et al. PLoS One
- Somatic mutations of the HER2 in metastatic breast cancer
- (2014) Yi Fang et al. TUMOR BIOLOGY
- Associations with growth factor genes (FGF1, FGF2, PDGFB, FGFR2, NRG2, EGF, ERBB2) with breast cancer risk and survival: the Breast Cancer Health Disparities Study
- (2013) Martha L. Slattery et al. BREAST CANCER RESEARCH AND TREATMENT
- A systematic review of dual targeting in HER2-positive breast cancer
- (2013) Iben Kümler et al. CANCER TREATMENT REVIEWS
- Human Breast Cancer Cells Harboring a Gatekeeper T798M Mutation in HER2 Overexpress EGFR Ligands and Are Sensitive to Dual Inhibition of EGFR and HER2
- (2013) B. N. Rexer et al. CLINICAL CANCER RESEARCH
- A High Frequency of Activating Extracellular Domain ERBB2 (HER2) Mutation in Micropapillary Urothelial Carcinoma
- (2013) J. S. Ross et al. CLINICAL CANCER RESEARCH
- HER1R497K andHER2I655V Polymorphisms Are Linked to Development of Breast Cancer
- (2013) Naglaa R. AbdRaboh et al. DISEASE MARKERS
- Lung Cancer That Harbors an HER2 Mutation: Epidemiologic Characteristics and Therapeutic Perspectives
- (2013) Julien Mazières et al. JOURNAL OF CLINICAL ONCOLOGY
- Novel Germline Mutation in the Transmembrane Domain of HER2 in Familial Lung Adenocarcinomas
- (2013) Hiromasa Yamamoto et al. JNCI-Journal of the National Cancer Institute
- Non–Small-Cell Lung Cancer with HER2 Exon 20 Mutation: Regression with Dual HER2 Inhibition and Anti-VEGF Combination Treatment
- (2013) Gerald S. Falchook et al. Journal of Thoracic Oncology
- Activating Mutations in HER2 : Neu Opportunities and Neu Challenges
- (2013) Britta Weigelt et al. Cancer Discovery
- Clinical Response to a Lapatinib-Based Therapy for a Li-Fraumeni Syndrome Patient with a Novel HER2V659E Mutation
- (2013) V. Serra et al. Cancer Discovery
- Activating Mutations in ERBB2 and Their Impact on Diagnostics and Treatment
- (2013) Grit S. Herter-Sprie et al. Frontiers in Oncology
- Prevalence, Clinicopathologic Associations, and Molecular Spectrum of ERBB2 (HER2) Tyrosine Kinase Mutations in Lung Adenocarcinomas
- (2012) M. E. Arcila et al. CLINICAL CANCER RESEARCH
- HER2 Mutations in Non–Small-Cell Lung Cancer Can Be Continually Targeted
- (2012) Ronan J. Kelly et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu
- (2012) J. De Grève et al. LUNG CANCER
- Advances in First-Line Treatment for Patients with HER-2+ Metastatic Breast Cancer
- (2012) L. De Mattos-Arruda et al. ONCOLOGIST
- Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2
- (2012) H. Greulich et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Activating HER2 Mutations in HER2 Gene Amplification Negative Breast Cancer
- (2012) Ron Bose et al. Cancer Discovery
- Identification of the Coexisting HER2 Gene Amplification and Novel Mutations in the HER2 Protein-Overexpressed Mucinous Epithelial Ovarian Cancer
- (2011) Wea-Lung Lin et al. ANNALS OF SURGICAL ONCOLOGY
- Effects of lapatinib monotherapy: results of a randomised phase II study in therapy-naive patients with locally advanced squamous cell carcinoma of the head and neck
- (2011) J M del Campo et al. BRITISH JOURNAL OF CANCER
- p95HER2 and Breast Cancer
- (2011) J. Arribas et al. CANCER RESEARCH
- Effectiveness of Tyrosine Kinase Inhibitors on "Uncommon" Epidermal Growth Factor Receptor Mutations of Unknown Clinical Significance in Non-Small Cell Lung Cancer
- (2011) J.-Y. Wu et al. CLINICAL CANCER RESEARCH
- Prognostic and predictive implications of HER2/ERBB2/neu gene mutations in lung cancers
- (2011) Kenji Tomizawa et al. LUNG CANCER
- Integrated genomic analyses of ovarian carcinoma
- (2011) D. Bell et al. NATURE
- The Human Splice Variant Δ16HER2 Induces Rapid Tumor Onset in a Reporter Transgenic Mouse
- (2011) Cristina Marchini et al. PLoS One
- Differential Sensitivity of ERBB2 Kinase Domain Mutations towards Lapatinib
- (2011) Rama Krishna Kancha et al. PLoS One
- Lack of association between HER2 codon 655 polymorphism and breast cancer susceptibility: meta-analysis of 22 studies involving 19,341 subjects
- (2010) Yanlei Ma et al. BREAST CANCER RESEARCH AND TREATMENT
- HER2 Ile655Val polymorphism contributes to breast cancer risk: evidence from 27 case–control studies
- (2010) Su Lu et al. BREAST CANCER RESEARCH AND TREATMENT
- A Major Role of p95/611-CTF, a Carboxy-Terminal Fragment of HER2, in the Down-modulation of the Estrogen Receptor in HER2-Positive Breast Cancers
- (2010) J. L. Parra-Palau et al. CANCER RESEARCH
- Cell Signaling by Receptor Tyrosine Kinases
- (2010) Mark A. Lemmon et al. CELL
- Quantitation of p95HER2 in Paraffin Sections by Using a p95-Specific Antibody and Correlation with Outcome in a Cohort of Trastuzumab-Treated Breast Cancer Patients
- (2010) J. Sperinde et al. CLINICAL CANCER RESEARCH
- The role of HER2 in cancer therapy and targeted drug delivery
- (2010) Wanyi Tai et al. JOURNAL OF CONTROLLED RELEASE
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
- (2010) Yung-Jue Bang et al. LANCET
- Diverse somatic mutation patterns and pathway alterations in human cancers
- (2010) Zhengyan Kan et al. NATURE
- Oncogenic mutations regulate tumor microenvironment through induction of growth factors and angiogenic mediators
- (2010) S E Wang et al. ONCOGENE
- Atomistic Insights into Regulatory Mechanisms of the HER2 Tyrosine Kinase Domain: A Molecular Dynamics Study
- (2009) Shannon E. Telesco et al. BIOPHYSICAL JOURNAL
- Resequencing and copy number analysis of the human tyrosine kinase gene family in poorly differentiated gastric cancer
- (2009) Takashi Kubo et al. CARCINOGENESIS
- HER2 codon 655 polymorphism is associated with advanced uterine cervical carcinoma
- (2009) Łukasz Kruszyna et al. CLINICAL BIOCHEMISTRY
- Understanding the Mechanisms Behind Trastuzumab Therapy for Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer
- (2009) Neil L. Spector et al. JOURNAL OF CLINICAL ONCOLOGY
- Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial
- (2009) Tetsuya Mitsudomi et al. LANCET ONCOLOGY
- A Naturally Occurring HER2 Carboxy-Terminal Fragment Promotes Mammary Tumor Growth and Metastasis
- (2009) K. Pedersen et al. MOLECULAR AND CELLULAR BIOLOGY
- An oncogenic isoform of HER2 associated with locally disseminated breast cancer and trastuzumab resistance
- (2009) D. Mitra et al. MOLECULAR CANCER THERAPEUTICS
- Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution
- (2009) Sohrab P. Shah et al. NATURE
- HER2YVMA drives rapid development of adenosquamous lung tumors in mice that are sensitive to BIBW2992 and rapamycin combination therapy
- (2009) S. A. Perera et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Impact of Common Epidermal Growth Factor Receptor and HER2 Variants on Receptor Activity and Inhibition by Lapatinib
- (2008) T. M. Gilmer et al. CANCER RESEARCH
- Mechanisms and strategies to overcome chemotherapy resistance in metastatic breast cancer
- (2008) Helen M. Coley CANCER TREATMENT REVIEWS
- HER2-targeted therapy in breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors
- (2008) Dorte Lisbet Nielsen et al. CANCER TREATMENT REVIEWS
- Acquired Resistance to Small Molecule ErbB2 Tyrosine Kinase Inhibitors
- (2008) F. L. Chen et al. CLINICAL CANCER RESEARCH
- EXEL-7647 Inhibits Mutant Forms of ErbB2 Associated with Lapatinib Resistance and Neoplastic Transformation
- (2008) T. Trowe et al. CLINICAL CANCER RESEARCH
- Somatic mutations affect key pathways in lung adenocarcinoma
- (2008) Li Ding et al. NATURE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now